Analysts Expect Osmotica Pharmaceuticals PLC (NASDAQ:OSMT) Will Post Quarterly Sales of $38.76 Million

Equities analysts expect Osmotica Pharmaceuticals PLC (NASDAQ:OSMT) to announce $38.76 million in sales for the current fiscal quarter, according to Zacks Investment Research. Three analysts have provided estimates for Osmotica Pharmaceuticals’ earnings, with the highest sales estimate coming in at $40.20 million and the lowest estimate coming in at $37.50 million. Osmotica Pharmaceuticals posted sales of $57.53 million during the same quarter last year, which would indicate a negative year-over-year growth rate of 32.6%. The firm is expected to issue its next quarterly earnings report on Thursday, August 13th.

On average, analysts expect that Osmotica Pharmaceuticals will report full-year sales of $172.11 million for the current fiscal year, with estimates ranging from $169.50 million to $175.80 million. For the next year, analysts anticipate that the firm will report sales of $197.47 million, with estimates ranging from $181.50 million to $221.81 million. Zacks Investment Research’s sales calculations are an average based on a survey of research firms that cover Osmotica Pharmaceuticals.

Osmotica Pharmaceuticals (NASDAQ:OSMT) last posted its quarterly earnings results on Tuesday, May 12th. The company reported ($0.05) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.12) by $0.07. Osmotica Pharmaceuticals had a negative net margin of 115.34% and a negative return on equity of 6.22%. The company had revenue of $48.65 million during the quarter, compared to analyst estimates of $43.76 million.

Several equities analysts have issued reports on the stock. Zacks Investment Research cut shares of Osmotica Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday. Wells Fargo & Co cut shares of Osmotica Pharmaceuticals from an “overweight” rating to an “equal weight” rating and set a $4.00 target price on the stock. in a research note on Monday, March 23rd. Royal Bank of Canada restated a “buy” rating and set a $10.00 target price on shares of Osmotica Pharmaceuticals in a research note on Wednesday, March 25th. SVB Leerink started coverage on shares of Osmotica Pharmaceuticals in a research note on Friday, March 6th. They set an “outperform” rating and a $10.00 target price on the stock. Finally, BidaskClub upgraded shares of Osmotica Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Thursday, June 25th. Three research analysts have rated the stock with a hold rating, four have issued a buy rating and one has given a strong buy rating to the company. Osmotica Pharmaceuticals has an average rating of “Buy” and a consensus price target of $7.79.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. State of New Jersey Common Pension Fund D bought a new stake in Osmotica Pharmaceuticals during the 1st quarter worth approximately $53,000. State Street Corp raised its stake in Osmotica Pharmaceuticals by 13.1% during the 1st quarter. State Street Corp now owns 164,320 shares of the company’s stock worth $523,000 after acquiring an additional 19,021 shares during the period. State of Tennessee Treasury Department raised its stake in Osmotica Pharmaceuticals by 175.3% during the 1st quarter. State of Tennessee Treasury Department now owns 10,149 shares of the company’s stock worth $32,000 after acquiring an additional 6,463 shares during the period. AQR Capital Management LLC bought a new stake in Osmotica Pharmaceuticals during the 1st quarter worth approximately $351,000. Finally, Engineers Gate Manager LP raised its stake in Osmotica Pharmaceuticals by 26.7% during the 1st quarter. Engineers Gate Manager LP now owns 41,182 shares of the company’s stock worth $131,000 after acquiring an additional 8,679 shares during the period. Institutional investors own 14.37% of the company’s stock.

Shares of OSMT stock opened at $6.73 on Wednesday. Osmotica Pharmaceuticals has a one year low of $2.70 and a one year high of $7.97. The company’s 50-day moving average is $5.62 and its 200 day moving average is $5.32. The company has a market capitalization of $350.34 million, a price-to-earnings ratio of -1.32 and a beta of 3.75. The company has a debt-to-equity ratio of 1.88, a quick ratio of 2.91 and a current ratio of 3.26.

Osmotica Pharmaceuticals Company Profile

Osmotica Pharmaceuticals plc, an integrated biopharmaceutical company, develops, manufactures, and commercializes specialty products that target markets with underserved patient populations. The company's promoted approved products include specialty neurology products, such as M-72 to treat ADHD; Osmolex ER for treating Parkinson's and drug-induced extrapyramidal reactions in adults; Lorzone for muscle spasms; ConZip to treat pain; and Ontinua ER for treating opioid withdrawal symptoms.

See Also: What is a management fee?

Get a free copy of the Zacks research report on Osmotica Pharmaceuticals (OSMT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Osmotica Pharmaceuticals (NASDAQ:OSMT)

Receive News & Ratings for Osmotica Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Osmotica Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.